Abstract library

7 results for "Laca".
#253 Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
Introduction: In our area the GEP NET incidence is similar to that of gastric and exocrine pancreatic cancers consequently being important to know their characteristics and the most convenient therapeutic approach.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#705 A Multi-Center Retrospective Evaluation of Neuroendocrine Tumors (Anatolian Society of Medical Oncology Group Study)
Introduction: Neuroendocrine tumors (NETs) are uncommon malignancies.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D Halit Karaca
Authors: Karaca H, Erol O, Ulas A, Demirci U, ...
#1279 Epidemiology Survival and Prognosis of Neuroendocrine Tumors: A Multidisciplinary Single-Center Study
Introduction: There is no certain consensus about prognostic factors of NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ersin Özaslan
#1379 Evaluation of the Concordance Between the Stage of the Disease and Ki-67 Proliferation Index in Gastroenteropancretic Neuroendocrine Tumors (GEP-NETs)
Introduction: .
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Ersin Özaslan
Authors: Özaslan E, Demir S, Karaca H, Güven K, ...
Keywords: grade, stage, NET
#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni
#1568 Neuroendocrine Neoplasm of the Colon and Rectum, Pathological and Clinical Characteristics, Based on pTNM WHO 2010 Classification
Introduction: Large bowel neuroendocrine neoplasms (NENs)
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Jaroslaw Cwikła
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.